Minimizing Risk When Investing in Biopharmas

Published April 13, 2013

Minimizing Risk When Investing In Biopharmas

Filed under: drug abuse treatment cost analysis program

However keep in mind it is their goal to sell their product to investors, and for this reason you must look at third party sources for analysis. Third party … Titan has taken the previously approved opioid addiction medication "Buprenorphine" which …
Read more on Seeking Alpha

Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing …

Filed under: drug abuse treatment cost analysis program

This agreement is part of our non-dilutive strategy aimed at minimizing R&D costs while maximizing drug development efficiency. Our goal for AEZS-108 with this collaboration, is to provide a much needed new treatment option to women with late-stage …
Read more on Sacramento Bee